Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction.

Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Abstract Text:

    yu-yu yaoYu-Yu Yao,hang yinHang Yin,bo shenBo Shen,lee chaoLee Chao,julie chaoJulie Chao,

    We investigated the effect of tissue kallikrein infusion on cardiac protection at acute and sub-acute phases after myocardial infarction (MI). Immediately after MI, rats were infused with purified tissue kallikrein, with or without icatibant (a kinin B2 receptor antagonist). Intramyocardial injection of kallikrein reduced myocardial infarct size and inhibited cardiomyocyte apoptosis at 1 day after MI associated with increased nitric oxide levels, Akt and glycogen synthase kinase-3beta phosphorylation and decreased caspase-3 activation. Kallikrein infusion for 7 days improved cardiac function, normalized left ventricular wall thickness and decreased monocyte/macrophage infiltration in the infarct heart. Kallikrein treatment reduced NADH oxidase expression and activity, superoxide formation and malondialdehyde levels, and reduced MAPK and Ikappa-Balpha phosphorylation, NF-kappaB activation and MCP-1 and VCAM-1 expression. Kallikrein's effects were all blocked by icatibant. These results indicate that kallikrein through kinin B2 receptor activation prevents apoptosis, inflammation and ventricular remodeling by increased nitric oxide formation and suppression of oxidative stress-mediated signaling pathways.

    Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Publishing Authors By Initials

    yy yaoYY Yao,h yinH Yin,b shenB Shen,l chaoL Chao,j chaoJ Chao,

    For similar circulatory and respiratory physiology: cardiovascular physiology: cardiovascular physiologic processes: ventricular function: ventricular remodeling research abstracts see: circulatory and respiratory physiology: cardiovascular physiology: cardiovascular physiologic processes: ventricular function: ventricular remodeling research

    PUBMED ID PMID:

    MEDLINE DATE:

    Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Journal Published:

    PUBLICATION TYPE: Research Support, N.I.H., Extr

    Journal: Regulatory peptides

    VOLUME: 140

    Page Numbers: 12-20

    Journal Abbreviation: Regul. Pept.

    ISSN: 0167-0115

    DAY: 28

    MONTH: 12

    YEAR: 2006

    Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8100479

    Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Keywords Mesh Terms:

    KEYWORDS: Ventricular Remodeling

    MESH TERMS: drug effects

    Chemical & Substance for Abstract: Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Information

    Substance Name: Tissue Kallikreins

    Registry Number: EC 3.4.21.35

    Grant and Affiliation Information for Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction.

    AFFILIATION: Atherosclerosis Research Centre, Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China.

    Country: Netherlands

    Netherlands Research PublicationNetherlands Research Publication

    AGENCY: United States NHLBI

    GRANT: R01 HL029397-24

    ACRONYM: HL

    MEDLINETA: Regul Pept

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News